Litcius/Paper detail

<i>In situ</i> tuning proangiogenic factor-mediated immunotolerance synergizes the tumoricidal immunity via a hypoxia-triggerable liposomal bio-nanoreactor

Chen Chen, Shengchang Zhang, Rui Zhang, Peng Sun, Chongdeng Shi, Mohnad Abdalla, Anning Li, Jiawen Xu, Wei Du, Jing Zhang, Ying Liu, Chunwei Tang, Zhenmei Yang, Xinyi Jiang

2020Theranostics29 citationsDOIOpen Access PDF

Abstract

Our work provides an alternative strategy for exerting efficient tumoricidal immunity in the proangiogenic factor-upregulated subpopulation of CRC patients and may have a wide-ranging impact on cancer immune-anti-angiogenic complementary therapy in clinics.

Topics & Concepts

NanoreactorHypoxia (environmental)LiposomePharmacologyImmunityMedicineImmune systemChemistryImmunologyBiochemistryOxygenOrganic chemistryCatalysisNanoplatforms for cancer theranosticsCancer Research and TreatmentsImmune cells in cancer
<i>In situ</i> tuning proangiogenic factor-mediated immunotolerance synergizes the tumoricidal immunity via a hypoxia-triggerable liposomal bio-nanoreactor | Litcius